IO Biotech's experimental cancer vaccine Cylembio failed to meet its primary goal in a phase 3 trial for advanced melanoma. The study evaluated Cylembio (imsapepimut and etimupepimut, adjuvanted) combined with Merck’s Keytruda (pembrolizumab) versus Keytruda alone in more than 400 patients with previously untreated advanced melanoma. While patients receiving the combination therapy showed improvement in progression-free survival, the results narrowly missed statistical significance.

Patients treated with the combination achieved a median progression-free survival of 19.4 months compared with 11 months for those receiving Keytruda alone, with a 23% reduction in the risk of disease progression or death.

“The magnitude and durability of clinical effect observed consistently across subgroups

See Full Page